Market Research Logo

Chronic Fatigue Syndrome Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Global Chronic Fatigue Syndrome Therapeutics Market:

About this market

Technavio’s chronic fatigue syndrome (CGS) therapeutics market analysis considers sales from pain relievers and NSAIDs, antidepressant and antipsychotic drugs, and antimicrobial and immunomodulatory drugs. Our analysis also considers the sales of chronic fatigue syndrome therapeutics in Asia, Europe, North America, and ROW. In 2018, the pain relievers and NSAIDs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as relieving patients from pain and reducing inflammation will play a significant role in the pain relievers and NSAIDs segment to maintain its market position. Also, our global chronic fatigue syndrome therapeutics market report looks at factors such as increasing use of off-label pharmacological treatment for CFS, increasing risk factors of CFS, and initiatives to increase awareness about CFS. However, lack of specific diagnostic tests for confirmation of CFS, lack of approved drugs for the treatment of CFS, and complex pathogenesis of CFS may hamper the growth of the chronic fatigue syndrome therapeutics industry over the forecast period.

Global Chronic Fatigue Syndrome Therapeutics Market: Overview

Increasing risk factors of CFS

Some theories indicate that viral infection, psychological stress, genetic factors increase the risk of CFS. The prevalence of CFS is four times more in women than in men. Chronic physical or emotional stress also may result in CFS. Stress affects the hypothalamic-pituitary-adrenal axis, which is a complex network that controls the body’s reaction, such as immune response, digestion, energy usage, and mood. The prevalence of stress is increasing globally due to many societal factors and work-related pressure which is increasing the risk factors of CFS. These risk factors of CFS will lead to the expansion of the global chronic fatigue syndrome therapeutics market at a CAGR of over 4% during the forecast period.

R&D of new drugs for the treatment of CFS

The lack of approved and effective drugs has led the vendors to focus on the R&D of novel drugs to cater to the unmet need in CFS pharmacological therapy. Researchers at Stanford University School of Medicine are harnessing the nanoelectronics-based diagnostic test, developed by them, to screen for drug-based treatments. These treatments are screened by adding controlled doses of several different potentially therapeutic drugs to the patient’s blood samples and performing diagnostic tests. The research funding for CFS has increased over the last couple of years. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global chronic fatigue syndrome therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global chronic fatigue syndrome therapeutics market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic fatigue syndrome therapeutics manufacturers, that include Hemispherx Biopharma Inc., Lupin Ltd., Mylan NV, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Also, the chronic fatigue syndrome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Pain relievers and NSAIDs - Market size and forecast 2018-2023
Antidepressant and antipsychotic drugs -
Market size and forecast 2018-2023
Antimicrobial and immunomodulatory drugs -
Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Development of new diagnostic tests for CFS
R&D of new drugs for the treatment of CFS
Increasing focus on investigation
Role of immune system in CFS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Hemispherx Biopharma, Inc.
Lupin Ltd.
Mylan NV
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Pain relievers and NSAIDs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Pain relievers and NSAIDs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antidepressant and antipsychotic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antidepressant and antipsychotic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Antimicrobial and immunomodulatory drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Antimicrobial and immunomodulatory drugs - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Hemispherx Biopharma Inc. - Vendor overview
Exhibit 47: Hemispherx Biopharma Inc. - Business segments
Exhibit 48: Hemispherx Biopharma Inc. - Organizational developments
Exhibit 49: Hemispherx Biopharma Inc. - Key offerings
Exhibit 50: Lupin Ltd. - Vendor overview
Exhibit 51: Lupin Ltd. - Business segments
Exhibit 52: Lupin Ltd. - Organizational developments
Exhibit 53: Lupin Ltd. - Geographic focus
Exhibit 54: Lupin Ltd. - Key offerings
Exhibit 55: Mylan NV - Vendor overview
Exhibit 56: Mylan NV - Product segments
Exhibit 57: Mylan NV - Organizational developments
Exhibit 58: Mylan NV - Geographic focus
Exhibit 59: Mylan NV - Segment focus
Exhibit 60: Mylan NV - Key offerings
Exhibit 61: Pfizer Inc. - Vendor overview
Exhibit 62: Pfizer Inc. - Business segments
Exhibit 63: Pfizer Inc. - Organizational developments
Exhibit 64: Pfizer Inc. - Geographic focus
Exhibit 65: Pfizer Inc. - Segment focus
Exhibit 66: Pfizer Inc. - Key offerings
Exhibit 67: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 68: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 69: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 70: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 71: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 72: Validation techniques employed for market sizing
Exhibit 73: Definition of market positioning of vendors

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report